Ask AI
ProCE Banner Activity

A New Paradigm In IgAN Management: How Diagnostics and Treatment Are Evolving

Clinical Thought

Learn what criteria must be met in clinical trials to approve novel therapies for IgA nephropathy (IgAN) and how the diagnostics and treatment landscape is evolving as a result of novel and emerging IgAN therapy data from these trials.

Released: November 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Kidney Fund (AKF).

ProCE Banner

Supporters

Supported by independent educational grants from Novartis Pharmaceuticals Corporation and Vertex Pharmaceuticals Incorporated.

Novartis Pharmaceuticals Corporation

Vertex Pharmaceuticals Incorporated

Partners

American Kidney Fund

ProCE Banner

Disclosure

Primary Author

Andrew S. Bomback, MD, MPH: consultant/advisor/speaker: Novartis, Otsuka, Travere.